Dyax - Advancing Novel Biotherapeutics

Dedicated to finding new solutions for patients in need.

Home>Investors>2010 Press releases

2010 Press releases

2010 | 2009 | 2008 | 2007 | 2006 | 2005
Keyword Search
 
DateTitle 
Feb 2, 2010KALBITOR(R) (ecallantide) Now Commercially Available
KALBITOR Orders Being Coordinated Through KALBITOR AccessSM --Call 1-888-452-5248 or Visit www.KALBITOR.com for Information CAMBRIDGE, Mass., Feb 02, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX) announced today that KALBITOR(R) (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older is now commercially available in the United States. HAE is a rare, genetic disorder characterized by severe, debilitating and often painful swelling... 
Printer Friendly Version
Feb 1, 2010Dyax Corp. to Present at the BIO CEO & Investor Conference
CAMBRIDGE, Mass., Feb 01, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A Christensen, President and Chief Executive Officer of Dyax, will present at the 12th Annual BIO CEO & Investor Conference, being held February 8-9th at The Waldorf-Astoria Hotel in New York, NY. Mr. Christensen will present a corporate progress report, including an update on the Company's commercial activities for KALBITOR(R) ... 
Printer Friendly Version
Jan 14, 2010Dyax Launches HAE Hope, A New Online Resource for Patients with Hereditary Angioedema
Website Offers Tools for Recognizing Attack Triggers and Managing the DiseaseCAMBRIDGE, Mass., Jan 14, 2010 (BUSINESS WIRE) -- A new, online resource is now available for patients with hereditary angioedema (HAE), their caregivers and physicians. The website, www.HAEHope.com, launched today by Dyax Corp. (NASDAQ: DYAX), offers resources to help patients and their families better understand and manage HAE, a rare, genetic disease characterized by episodes of severe and painful swelling. A numbe... 
Printer Friendly Version
2010 | 2009 | 2008 | 2007 | 2006 | 2005

Stock quote

ExchangeNASDAQ (US Dollar)
Price$3.22
Change (%) Stock is Down 0.16 (4.73%)
See more

IR Tool Kit

E-mail Alerts  E-mail Alerts
IR Contacts  IR Contacts
RSS Feeds  RSS Feeds
Investor Kit  Online Investor Kit

Investor Relations Contacts

Ivana Magovčević-Liebisch
Executive Vice President Corporate Development and General Counsel
Dyax Corp.
Phone: 617-225-2500


Nicole Jones
Director, Investor Relations and Corporate Communications
Dyax Corp.
Phone: 617-225-2500


Ellen Flipse Decareau
Senior Investor Relations and Corporate Communications Specialist
Dyax Corp.
Phone: 617-225-2500

See All